The efficacy of escitalopram, compared with duloxetine, for the treatment of acute major depressive disorder varied over multiple measures, but escitalopram showed higher tolerability than duloxetine in a new study.READ MORE
Adults who exercise report 1.5 fewer days of poor mental health each month, compared with people who do not exercise, according to a study published online in The Lancet Psychiatry.READ MORE
The Brainsway Deep Transcranial Magnetic Stimulation (TMS) System was previously cleared for use in patients with major depression and pain from certain migraine headaches. What condition is the new approval for?READ MORE
Between 1 and 2 daily milligrams of adjunctive cariprazine eased depression more than placebo in patients with major depressive disorder, according to a newly published study.READ MORE
Psych Congress Steering Committee member Jon Draud, MD, MS, discusses the use of transcranial magnetic stimulation (TMS) in psychiatry, including its benefits, side effects, and potential applications.READ MORE
Psych Congress Year-Round
Michael Thase, MD, will review data on emerging medications for depression, outline the pathophysiology of depression, and discuss the limitations of available treatments in a session at the upcoming Psych Congress 2018 conference.
COLUMBUS, Ohio—Psych Congress cochair Charles Raison, MD, gave attendees a “10,000-foot view” of what depression is at the Psych Congress Regionals meeting here, and will explore the idea more at the upcoming Psych Congress 2018 preconference.